Nikolaos Perakakis

List of Publications by Year
in descending order

40 papers	2,258 citations	346980 22 h-index	371746 37 g-index
40 all docs	40 docs citations	40 times ranked	3917 citing authors

#	Article	IF	Citations
1	Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial. Metabolism: Clinical and Experimental, 2022, 129, 155157.	1.5	8
2	PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses. Metabolism: Clinical and Experimental, 2022, 134, 155265.	1.5	4
3	Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of rewardâ€•and attentionâ€•related brain centres in response to visual food cues in adults with obesity: A crossâ€•sectional functional <scp>MRI</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1202-1207.	2.2	9
4	Leptin in Leanness and Obesity. Journal of the American College of Cardiology, 2021, 77, 745-760.	1.2	49
5	Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of nonâ€alcoholic steatohepatitis. Liver International, 2021, 41, 1853-1866.	1.9	21
6	Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH. Journal of the Endocrine Society, 2021, 5, A314-A315.	0.1	0
7	Branched-Chain Amino Acids in relation to food preferences and insulin resistance in obese subjects consuming walnuts: A cross-over, randomized, double-blind, placebo-controlled inpatient physiology study. Clinical Nutrition, 2021, 40, 3032-3036.	2.3	5
8	Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. International Journal of Molecular Sciences, 2021, 22, 6332.	1.8	15
9	Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e390-e400.	1.8	29
10	Quantifying Fibrinogen-Dependent Aggregation of Red Blood Cells in Type 2 Diabetes Mellitus. Biophysical Journal, 2020, 119, 900-912.	0.2	31
11	Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment. Metabolism: Clinical and Experimental, 2020, 113, 154392.	1.5	7
12	The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154320.	1.5	68
13	Leptin alters energy intake and fat mass but not energy expenditure in lean subjects. Nature Communications, 2020, 11, 5145.	5.8	48
14	The Selective Peroxisome Proliferatorâ€Activated Receptor Gamma Modulator CHSâ€131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. Hepatology Communications, 2020, 4, 1302-1315.	2.0	13
15	The Role of Glicentin and Oxyntomodulin in Human Metabolism: New Evidence and New Directions. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3003-e3005.	1.8	19
16	Metabolic regulation of activins in healthy individuals and in obese patients undergoing bariatric surgery. Diabetes/Metabolism Research and Reviews, 2020, 36, e3297.	1.7	7
17	Sex specific effect of ATPase inhibitory factor 1 on body weight: studies in high fat diet induced obese mice and genetic association studies in humans. Metabolism: Clinical and Experimental, 2020, 105, 154171.	1.5	6
18	Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?. Metabolism: Clinical and Experimental, 2019, 98, iii-ix.	1.5	24

#	Article	IF	Citations
19	Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovascular Diabetology, 2019, 18, 141.	2.7	30
20	Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials. Metabolism: Clinical and Experimental, 2019, 101, 153997.	1.5	62
21	Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism: Clinical and Experimental, 2019, 96, 66-82.	1.5	72
22	Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A sixâ€•month, randomized, placeboâ€•controlled, doubleâ€•blind clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 1487-1492.	2.2	38
23	Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism: Clinical and Experimental, 2019, 101, 154005.	1.5	83
24	Follistatins in glucose regulation in healthy and obese individuals. Diabetes, Obesity and Metabolism, 2019, 21, 683-690.	2.2	36
25	Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism: Clinical and Experimental, 2019, 92, 170-192.	1.5	184
26	Stem cells in the treatment of diabetes mellitus â€" Focus on mesenchymal stem cells. Metabolism: Clinical and Experimental, 2019, 90, 1-15.	1.5	88
27	Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls. Hormone and Metabolic Research, 2019, 51, 112-119.	0.7	7
28	Research advances in metabolism 2017. Metabolism: Clinical and Experimental, 2018, 83, 280-289.	1.5	0
29	Pharmacotherapy of type 2 diabetes: An update. Metabolism: Clinical and Experimental, 2018, 78, 13-42.	1.5	144
30	Obesity as a Disease. Medical Clinics of North America, 2018, 102, 13-33.	1.1	256
31	Irisin in metabolic diseases. Endocrine, 2018, 59, 260-274.	1.1	178
32	Antitumor and antimetastatic effects of walnut oil in esophageal adenocarcinoma cells. Clinical Nutrition, 2018, 37, 2166-2171.	2.3	25
33	Physiology of Activins/Follistatins: Associations With Metabolic and Anthropometric Variables and Response to Exercise. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3890-3899.	1.8	31
34	Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism, 2018, 33, 33.	1.3	120
35	Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function. Metabolism: Clinical and Experimental, 2018, 85, 240-249.	1.5	32
36	Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics. Metabolism: Clinical and Experimental, 2018, 87, A1-A9.	1.5	83

#	Article	IF	Citations
37	Physiology and role of irisin in glucose homeostasis. Nature Reviews Endocrinology, 2017, 13, 324-337.	4.3	403
38	Research advances in metabolism 2016. Metabolism: Clinical and Experimental, 2017, 67, 41-53.	1.5	0
39	Adiponectin administration prevents weight gain and glycemic profile changes in diet-induced obese immune deficient Rag1â^'/â^' mice lacking mature lymphocytes. Metabolism: Clinical and Experimental, 2016, 65, 1720-1730.	1.5	15
40	Immune therapy in type 1 diabetes mellitus â€" Attempts to untie the Gordian knot?. Metabolism: Clinical and Experimental, 2016, 65, 1278-1285.	1.5	8